KPV

Overview

KPV’s primary appeal is its combination of potent gut anti-inflammatory activity and unusual oral bioavailability for a peptide. Most peptides are degraded in the gastrointestinal tract before absorption; KPV’s small size (tripeptide) and stability allow meaningful oral delivery, potentially simplifying administration for gut-targeted applications.

IBD Research

The animal data for IBD is promising — particularly in DSS-induced colitis models where KPV shows histological improvements, reduced inflammatory markers, and preserved intestinal architecture. The mechanistic rationale (NF-kB inhibition in gut epithelium) is sound. No human trials have been conducted.

Alpha-MSH Connection

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH (alpha-melanocyte stimulating hormone), which has known anti-inflammatory properties. KPV retains this activity in a smaller, more stable, more bioavailable format — a classic peptide fragment optimization.

Research Priority

Of the “gut healing” peptides, KPV has one of the cleaner mechanistic profiles and one of the better arguments for oral delivery. It represents a genuine research opportunity, though the translation from animal models to human IBD remains to be demonstrated.